Literature DB >> 16542288

Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review.

Agostino Colli1, Mirella Fraquelli, Giovanni Casazza, Sara Massironi, Alice Colucci, Dario Conte, Piergiorgio Duca.   

Abstract

BACKGROUND AND AIM: In patients with chronic liver disease, the accuracy of ultrasound scan (US), spiral computed tomography (CT), magnetic resonance imaging (MRI), and alpha-fetoprotein (AFP) in diagnosing hepatocellular carcinoma (HCC) has never been systematically assessed, and present systematic review was aimed at this issue.
METHODS: Pertinent cross-sectional studies having as a reference standard pathological examinations of the explanted liver or resected segment(s), biopsies of focal lesion(s), and/or a period of follow-up, were identified using MEDLINE, EMBASE, Cochrane Library, and CancerLit. Pooled sensitivity, specificity, and likelihood ratios (LR) were calculated using the random effect model. Summary receiver operating characteristic (SROC) curve and predefined subgroup analyses were made when indicated.
RESULTS: The pooled estimates of the 14 US studies were 60% (95% CI 44-76) for sensitivity, 97% (95% CI 95-98) for specificity, 18 (95% CI 8-37) for LR+, and 0.5 (95% CI 0.4-0.6) for LR-; for the 10 CT studies sensitivity was 68% (95% CI 55-80), specificity 93% (95% CI 89-96), LR+ 6 (95% CI 3-12),and LR- 0.4 (95% CI 0.3-0.6); for the nine MRI studies sensitivity was 81% (95% CI 70-91), specificity 85% (95%CI 77-93), LR+ 3.9 (95%CI 2-7), and LR- 0.3 (95% CI 0.2-0.5). The sensitivity and specificity of AFP varied widely, and this could not be entirely attributed to the threshold effect of the different cutoff levels used.
CONCLUSIONS: US is highly specific but insufficiently sensitive to detect HCC in many cirrhotics or to support an effective surveillance program. The operative characteristics of CT are comparable, whereas MRI is more sensitive. High-quality prospective studies are needed to define the actual diagnostic role of AFP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16542288     DOI: 10.1111/j.1572-0241.2006.00467.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  138 in total

1.  Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.

Authors:  Mariya L Samoylova; Jennifer L Dodge; Neil Mehta; Francis Y Yao; John P Roberts
Journal:  Clin Transplant       Date:  2014-12-01       Impact factor: 2.863

2.  Chronological evaluation of liver enhancement in patients with chronic liver disease at Gd-EOB-DTPA-enhanced 3-T MR imaging: does liver function correlate with enhancement?

Authors:  Shinichi Nakamura; Kazuo Awai; Daisuke Utsunomiya; Tomohiro Namimoto; Takeshi Nakaura; Kosuke Morita; Yasuyuki Yamashita
Journal:  Jpn J Radiol       Date:  2011-12-14       Impact factor: 2.374

3.  Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.

Authors:  Tianlu Chen; Guoxiang Xie; Xiaoying Wang; Jia Fan; Yunping Qiu; Xiaojiao Zheng; Xin Qi; Yu Cao; Mingming Su; Xiaoyan Wang; Lisa X Xu; Yun Yen; Ping Liu; Wei Jia
Journal:  Mol Cell Proteomics       Date:  2011-04-25       Impact factor: 5.911

4.  Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Lorenzo Andreana; Graziella Isgrò; Maria Pleguezuelo; Giacomo Germani; Andrew K Burroughs
Journal:  World J Hepatol       Date:  2009-10-31

5.  Studies on Budd-chiari syndrome complicated with hepatocellular carcinoma: most patients without inferior vena cava obstruction.

Authors:  Xiaowei Dang; Luhao Li; Suxin Li; Yafei Wang; Hai Li; Shaokai Xu; Peiqin Xu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

6.  A premature proposal for new liver cancer seromarkers.

Authors:  Liu-Cheng Wu; Wen-Feng Gong; Jian-Hong Zhong
Journal:  Tumour Biol       Date:  2016-01-13

Review 7.  Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.

Authors:  Danijel Galun; Dragan Basaric; Marinko Zuvela; Predrag Bulajic; Aleksandar Bogdanovic; Nemanja Bidzic; Miroslav Milicevic
Journal:  World J Hepatol       Date:  2015-09-18

8.  Diagnostic test systematic reviews: bibliographic search filters ("Clinical Queries") for diagnostic accuracy studies perform well.

Authors:  Monika Kastner; Nancy L Wilczynski; Ann K McKibbon; Amit X Garg; R Brian Haynes
Journal:  J Clin Epidemiol       Date:  2009-02-20       Impact factor: 6.437

9.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

10.  Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients.

Authors:  Massimo Galia; Francesco Agnello; Gianvincenzo Sparacia; Domenica Matranga; Domenico Albano; Massimo Midiri; Roberto Lagalla
Journal:  Radiol Med       Date:  2018-03-15       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.